Genmab chief executive Jan van de Winkel, photographed for the company; the image is company-relevant, not a photograph of a clinical trial. Health Genmab shares jump 13.7 percent as investors react to two Friday cancer readouts Mono Scoops 2d Genmab shares jumped 13.7 percent in European trading on Monday as investors reacted to Friday’s ESMO readouts: a Phase 3 ovarian cancer win for rinatabart sesutecan and updated Phase 2 colorectal data for petosemtamab. Read Full Story
